Why Galectin Therapeutics Inc.’s (GALT) Stock Is Up 5.05%
As of Tuesday, September 22, Galectin Therapeutics Inc.’s GALT share price has surged by 5.05%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company’s lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension. It has a joint venture co-owned by SBH Sciences, Inc. to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
Commentary & Analysis
Why Galectin Therapeutics Inc.’s (GALT) Stock Is Down 5.47%
As of Tuesday, September 15, Galectin Therapeutics Inc.’s GALT share price has dipped by 5.47%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Galectin Therapeutics Inc.’s (GALT) Stock Is Down 6.62%
As of Tuesday, September 08, Galectin Therapeutics Inc.’s GALT share price has dipped by 6.62%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Galectin Therapeutics Inc.’s (GALT) Stock Is Up 6.00%
As of Wednesday, September 02, Galectin Therapeutics Inc.’s GALT share price has surged by 6.00%, which has investors questioning if this is right time to sell.Michael Rose
Why Galectin Therapeutics Inc.’s (GALT) Stock Is Up 6.84%
As of Tuesday, September 01, Galectin Therapeutics Inc.’s GALT share price has surged by 6.84%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Financial Summary
| Share Statistics | GALT | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $399.4 | $261.1 | 35% |
|
| Shares Out (Mil) | 65.9 | 54.3 | 54% |
|
| Institutional Ownership | 25.1% | 92.9% | 11% |
|
| Float (Mil) | 47.8 | 41.5 | 46% |
|
| Beta | 0.39 | 0.95 | 22% |
|
| Avg Daily Volume (000s) | 327 | 677 | 50% |
|
| Price Change (52-week) |
(17.7%) | 51.8% | 36% |
|
| Growth | GALT | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.2% | na |
|
| Net Income (5yr) | (5.6%) | (10.1%) | 33% |
|
| EPS (5yr) | (3.2%) | 15.8% | 27 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | 16.1% | (15.6%) | 75% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | GALT | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($28) | ($43) | 21% |
|
| EPS (TTM) | ($0.430) | ($1.600) | 29% |
|
| Operating Cash Flow (TTM) (Mil) | ($16) | ($32) | 17% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 9% |
|
| Enterprise Value (Q1) (Mil) | $525 | $174 | 34% |
|
| Valuation | GALT | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.52 | na |
|
| P/E | na | 19.5 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | GALT | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 68.9% | na |
|
| Net Margin | na | (72.5%) | na |
|
| ROA | (183.0%) | (47.5%) | 2% |
|
| ROE | 21.5% | (54.9%) | 81% |
|
| Liabilities to Assets | na | 29.4% | na |
|
| F-Score | 3 | 3 | 18% |
|
Galectin Therapeutics Inc. did not pass any screens on 9/24/2026.
